Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia

NCT01960413 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)

Interventions

DRUG: Montelukast added to Hydroxyurea
DRUG: Placebo added to Hydroxyurea

Sponsor

Vanderbilt University Medical Center

Collaborators

[object Object]
[object Object]